Laborie Medical Technologies Archives - Medical Design Sourcing

Laborie acquires drug-coated balloon maker Urotronic

The Optilume BPH catheter system drug-coated balloon. [Image courtesy of Urotronic]Laborie Medical Technologies announced today that it completed the acquisition of drug-coated balloon developer Urotronic.

The companies struck an agreement last month for Laborie to buy Urotronic for up to $600 million.

Urotronic developed the Optilume DCB used in interventional urology procedures. It treats urethral strictures and benign prostatic hyperplasia (BPH) or enlarged prostate conditions.

Minneapolis-based Laborie acquired exclusive rights to Optilume in January 2022. The system combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel.

Under the terms of the acquisition, Laborie intends to pay $255 million upfront in cash. It also includes up to $345 million in potential commercial and reimbursement milestones. Net of Laborie’s existing minority investment in Urotronic, the deal comes to $232…

Laborie acquires exclusive license for drug-coated baloon treatment for urethral strictures

Laborie Medical Technologies announced today that it acquired an exclusive license to the Optilume urethral drug-coated balloon (DCB).

Portsmouth, New Hampshire-based Laborie purchased a perpetual, exclusive license to Optilume — developed by Urotronic — following FDA approval in December 2021. The DCB platform received CE mark approval for use in male anterior urethral strictures in 2020.

Get the full story at our sister site, Drug Delivery Business News.

Laborie acquires Pelvalon and its device for treating fecal incontinence

Laborie Medical Technologies announced that it acquired Pelvalon and its Eclipse non-surgical device for treating fecal incontinence.

Redwood City, California-based Pelvalon designed the FDA-cleared Eclipse system as a patient-controlled device for women suffering from fecal incontinence, according to a news release.

Portsmouth, N.H.-based Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Financial terms for the acquisition were not disclosed.

“Laborie’s mission every day is to operate as a world-class specialist medical company making and advancing technologies that preserve and restore human dignity,” Laborie president & CEO Michael Frazzette said in the release. “Our mission is well served by the addition of Eclipse to help pa…